Clinical trials: CONTROL Condition
Chronic Schizophrenia
Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR long term…
- Trial name
- PEARL 3 Ext (NCT00789698)
- Testing
- Lurasidone HC1, Quetiapine XR
- Where
- 65 sites in United States, Colombia and 4 more
- Volunteers
- 240 people
- Sponsor
- Sumitomo Pharma America, Inc.
Spasticity in People With Multiple Sclerosis
Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis
Phase II a Proof of concept study in Multiple Sclerosis (MS) patients with spasticity.
- Trial name
- NCT02542787
- Testing
- VSN16R
- Where
- 4 sites in United Kingdom
- Volunteers
- 160 people
- Sponsor
- Canbex Therapeutics Ltd
Diabetes Mellitus, Type 2
Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes
This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics of multiple ascending doses of PF-05231023.
- Trial name
- NCT01396187
- Testing
- PF-05231023
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Pfizer
Breast Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in…
- Trial name
- INAVO123 (NCT06790693)
- Testing
- Inavolisib, CDK4/6i, Letrozole
- Where
- 242 sites in United States, Argentina and 18 more
- Volunteers
- 450 people
- Sponsor
- Hoffmann-La Roche
Ischemic Stroke
IMPACT- 24Bt Post Mech. Thrombectomy and/or rtPA TRIAL IMPlant Augmenting Cerebral Blood Flow 24 Hours From Stroke Onset
The primary objective of the study is to assess the safety and effectiveness of SPG stimulation with the ISS in a 24 hour window, in patients with an acute ischemic stroke in the anterior circulation, who received Mechanical…
- Trial name
- IMPACT-24Bt (NCT01874093)
- Testing
- The Ischemic Stroke System
- Where
- Spain
- Volunteers
- 27 people
- Sponsor
- BrainsGate
Infections, Meningococcal
Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults
The purpose of this study was to evaluate the effectiveness of 2 doses or 3 doses of GSK's licenced meningococcal group B Bexsero (rMenB+OMV NZ) vaccine and of 2 doses of GSK's investigational combined meningococcal (MenABCWY)…
- Trial name
- NCT04502693
- Testing
- rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), MenABCWY-1
- Where
- 112 sites in United States, Australia and 5 more
- Volunteers
- 3,657 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Smoking Cessation
Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking
The primary purpose of this study is to determine whether or not varenicline will help people with cardiovascular disease quit smoking and to confirm it is safe in these patients.
- Trial name
- NCT00282984
- Testing
- Varenicline
- Where
- 39 sites in United States, Argentina and 13 more
- Volunteers
- 714 people
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
Phase 1b/2 Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT07143448
- Testing
- HS235
- Where
- 7 sites in United States, Spain and 1 more
- Volunteers
- 90 people
- Sponsor
- 35Pharma Inc., a GSK company
Major Depressive Disorder
Dose-finding Study With Lu AA24530 in Major Depressive Disorder
The primary purpose of this study is to assess the efficacy in treating patients with Major Depressive Disorder of one or more doses of Lu AA24530 relative to placebo
- Trial name
- NCT00599911
- Testing
- Lu AA24530, Duloxetine
- Where
- 72 sites in Australia, Austria and 15 more
- Volunteers
- 652 people
- Sponsor
- H. Lundbeck A/S
Presbyopia
A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.
The purpose of this study was to assess the effect of topical UNR844-Cl (lipoic acid choline ester chloride) ophthalmic solution on near visual function in presbyopic subjects.
- Trial name
- NCT03809611
- Testing
- UNR844-Cl
- Where
- 14 sites in United States
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C, Chronic
4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients
The main purpose of this clinical trial with BI 207127 is to see the effect of 4 week combination of BI 207127 with Peginterferon alfa (Peg-IFN) and Ribavirin (RBV) on hepatitis C virus (HCV) virus load and how safe BI 207127 is…
- Trial name
- NCT00905632
- Testing
- BI 207127 middle dose +SOC, BI 207127 high dose+SOC, BI 207127 low dose + SOC
- Where
- 18 sites in France, Germany and 1 more
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Asthma
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function…
- Trial name
- ATLAS (NCT05097287)
- Testing
- Dupilumab
- Where
- 249 sites in United States, Belgium and 21 more
- Volunteers
- 1,339 people
- Sponsor
- Sanofi
Allergic Rhinitis, Perennial Allergic Rhinitis
Clinical Trial to Evaluate the Safety and Efficacy of AGR Tablet as a Treatment of Perennial Allergic Rhinitis in Korean
The purpose of this study is to evaluate treatment of perennial allergic rhinitis in Korean patients with AGR tablet.
- Conditions
- Allergic Rhinitis, Perennial Allergic Rhinitis, Non-seasonal Allergic Rhinitis
- Trial name
- NCT01982916
- Testing
- AGR tablet, Active Comparator
- Where
- 9 sites in South Korea
- Volunteers
- 324 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Dry Eye Disease
A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease
A Randomized, Double-Masked, Vehicle-Controlled Parallel Group Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
- Trial name
- NCT06389214
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 132 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Hepatitis B, Chronic
Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue
The purpose of this study is to evaluate the efficacy and safety of GSK548470 administered once daily at a dose level of 300 mg to Japanese patients with compensated chronic hepatitis B untreated with any nucleic acid analogue.
- Trial name
- NCT01480284
- Testing
- GSK548470 300 mg tablet, ETV 0.5 mg capsule
- Where
- 32 sites in Japan
- Volunteers
- 166 people
- Sponsor
- GlaxoSmithKline
Hepatitis B
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.
- Trial name
- B-Focus (NCT06497504)
- Testing
- Bepirovirsen
- Where
- 51 sites in United States, Argentina and 8 more
- Volunteers
- 153 people
- Sponsor
- GlaxoSmithKline
Nonalcoholic Steatohepatitis (NASH)
Multiple Dose Safety, Tolerability, PK，PD and Food Effect Study of HEC96719 in Healthy Adult Subjects
The Safety, Tolerability, Pharmacokinetic, Pharmacodynamics and Food Effect Study of HEC96719 in Healthy Subjects
- Trial name
- NCT04546984
- Testing
- HEC96719
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Irritable Bowel Syndrome
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
The objective of this study is to evaluate the safety and efficacy of LX1033 over a range of dose levels in subjects with diarrhea-predominant Irritable Bowel Syndrome (IBS).
- Trial name
- NCT01494233
- Testing
- 250 mg LX1033 tablets
- Where
- 81 sites in United States
- Volunteers
- 373 people
- Sponsor
- Lexicon Pharmaceuticals
Opioid-induced Constipation
Long Term Safety of Naldemedine
The purpose of this study is to evaluate the long-term safety of naldemedine for the treatment of constipation due to opioid therapy.
- Trial name
- NCT01965652
- Testing
- Naldemedine
- Where
- 186 sites in United States, Australia and 14 more
- Volunteers
- 1,246 people
- Sponsor
- Shionogi
HIV Infections
Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)
This protocol represents the third in human study of TUTI-16, and is being conducted to gather additional safety and human immunogenicity (anti-HIV-1 Tat titers) data of subcutaneously administered TUTI-16.
- Trial name
- NCT01335191
- Testing
- TUTI-16 (1.0 mg)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Thymon, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.